Tag: Medical Research
Novel approach also shows promise for autoimmune diseases
Paralyzing damage in spinal cord injury (SCI) is often caused by the zealous immune response to the injury. NIBIB-funded engineers have developed nanoparticles that lure immune cells away from the spinal cord, allowing regeneration that restored spinal cord function in mice.
The brain-computer interface lets paralyzed people type using their thoughts.
For the first time, doctors are preparing to test a brain-computer interface that can be implanted onto a human brain, no open surgery required.
The Stentrode, a neural implant that can let paralyzed people communicate, can be delivered to a patient’s brain through the jugular vein — and the company that developed it, Synchron, just got approval to begin human experimentation.
A new electromyography biofeedback device that is wearable and connects to novel smartphone games may offer people with incomplete paraplegia a more affordable, self-controllable therapy to enhance their recovery, according to a new study presented this week at the Association of Academic Physiatrists Annual Meeting in Puerto Rico.
Electromyography (recording electrical activity of muscles) biofeedback has been shown to enhance recovery of muscle control in people with incomplete spinal cord injury.
Patients with spinal cord injury or disease (SCI/D) are 3 to 4 times more likely to have sleep disordered breathing (SDB) than individuals in the general population. The prevalence of SDB — both central and obstructive sleep apnea — ranges from 27% to 82% in patients with subacute and chronic SCI/D.
The Why and How of SDB in SCI
The type of spinal cord injury affects the prevalence of SDB; patients with quadriplegia are more likely to have SDB than patients with paraplegia.
Derived from human pluripotent stem cells, these diverse cells advance disease modeling and may provide new, scalable source of replacement cells for spinal cord injuries
Researchers at University of California San Diego School of Medicine report that they have successfully created spinal cord neural stem cells (NSCs) from human pluripotent stem cells (hPSCs) that differentiate into a diverse population of cells capable of dispersing throughout the spinal cord and can be maintained for long periods of time.
Spinal cord injuries are among the most severe and difficult-to-treat medical conditions, usually resulting in permanent disability including loss of muscle function, sensation and autonomic functions. Medical research is now on the cusp of treating severe spinal cord injuries by inducing the repair of spinal nerves, and scientists have made strides in recent years with rodents and primates.
Using chitosan loaded with neurotrophin-3 (NT3), a collaborative of Chinese medical researchers now reports the successful treatment and subsequent functional recovery of rhesus monkeys with induced acute spinal cord injuries.
Dr. Ona E. Bloom, Feinstein Institute for Medical Research , associate professor has uncovered that white blood cell genes are present at different levels in people with spinal cord injury.
These findings, published yesterday online in the “Journal of Neurotrauma,” are a first step to understanding and developing better interventions for infections in people with spinal cord injury, which is the leading cause of death in these individuals.
Spinal cord injury affects the heart, that’s what research published in Experimental Physiology and carried out by researchers from University of British Columbia, Canada has found.
The heart undergoes changes after spinal cord injury that are dependent on how severe the spinal cord injury is but only a small amount of “sparing” (i.e., a small number of nerve fibers preserved) in the spinal cord are necessary for the heart to function at a near normal level.
Lengthy study finds that implanted neural stem cells grow slow and steady, and success needs to be measured accordingly
More than one-and-a-half years after implantation, researchers at University of California San Diego School of Medicine and the San Diego Veterans Administration Medical Center report that human neural stem cells (NSCs) grafted into spinal cord injuries in laboratory rats displayed continued growth and maturity, with functional recovery beginning one year after grafting.
Researchers at ReNetX Bio are hoping a new name, the potential for a new influx of cash on the horizon and a new chief executive officer are the winning combination needed to bring its lead drug candidate to market.
ReNetX Bio is looking to guide its drug candidate, Nogo Trap, through its first round of clinical trials. Company officials say Nogo Trap is designed to help patients with chronic spinal cord injury.